01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
20:14 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Shanghai Henlius up for Hong Kong IPO

Biosimilars company Shanghai Henlius Biotech Inc. (Shanghai, China) proposed on Dec. 14 to list on the Hong Kong stock exchange. Shanghai Henlius' lead compound is HLX01, a biosimilar of cancer and autoimmune drug MabThera rituximab...
00:06 , Dec 15, 2018 |  BC Extra  |  Financial News

Shanghai Henlius up for Hong Kong IPO

Biosimilars company Shanghai Henlius Biotech Inc. (Shanghai, China) proposed on Friday to list on the Hong Kong stock exchange. Shanghai Henlius' lead compound is HLX01, a biosimilar of cancer and autoimmune drug MabThera rituximab from...
19:26 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Shanghai Henlius to move forward with Hong Kong listing

Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) said on Sept. 27 its board approved a resolution to list Shanghai Henlius Biotech Inc. (Shanghai, China) on the Hong Kong stock exchange. Shanghai Henlius, a JV...
22:19 , Mar 16, 2018 |  BioCentury  |  Finance

Hong Kong’s new chapter

Introducing a biotech chapter to the Hong Kong stock exchange fills a massive void in the region’s innovation ecosystem, but won’t come without risks. It promises to create a long sought public capital market for...
20:49 , Jan 5, 2018 |  BC Week In Review  |  Financial News

Fosun's biosimilar unit to raise $190M

Shanghai Henlius Biotech Inc. (Shanghai, China) said on Dec. 21, 2017, it will raise RMB1.3 billion ($192.5 million) through the sale of 55.4 million shares at RMB22.71, including 14.6 million shares to its parent company...
23:59 , Dec 28, 2017 |  BC Extra  |  Financial News

Fosun's biosimilar unit to raise $190M

On Dec. 20, Shanghai Henlius Biotech Inc. (Shanghai, China) said it will raise RMB1.3 billion ($192.5 million) through the sale of 55.4 million shares at RMB22.71, including 14.6 million shares to its parent company Fosun...
21:20 , Nov 9, 2017 |  BC Innovations  |  Finance

The return of big

After a slow second quarter, pharmas have stepped up their activity in public-private partnerships, announcing 13 in 3Q17, compared with only five in the quarter before. The deals bring the third quarter total to 56,...
20:12 , Sep 22, 2017 |  BC Week In Review  |  Financial News

AbClon raises W6.8B in IPO

On Sept. 18, AbClon Inc. (KOSDAQ:174900) raised W6.8 billion ($6.1 million) through the sale of 680,741 shares at W10,000 in an IPO. Director Kyu-Tae Kim told BioCentury that AbClon's lead candidate is AC101 , a...
19:21 , Sep 19, 2017 |  BC Extra  |  Financial News

AbClon continues to rise after IPO

Korean biotech AbClon Inc. (KOSDAQ:174900) gained W4,050 (16%) to W30,050 in its second day of trading Tuesday. The closing price values the company at W204.4 billion ($183.9 million). On its first day of trading Monday,...